MRK:NYE-Merck & Company Inc. (new)

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 61.03

Change

+0.04 (+0.07)%

Market Cap

USD 164.19B

Volume

0.01B

Yahoo Analyst Target

USD 69.06 (13.16%)

STA Analyst Target

USD 64.62 (5.89%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, and animal health.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-06-19 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.25 (+1.03%)

USD 328.75B
PFE Pfizer Inc.

+0.06 (+0.17%)

USD 211.87B
NVS Novartis AG

-0.52 (-0.70%)

USD 171.48B
ABBV AbbVie Inc.

-0.47 (-0.48%)

USD 155.53B
GSK GlaxoSmithKline PLC

-0.23 (-0.56%)

USD 101.77B
SNY Sanofi American Depositary Sha..

-0.44 (-1.11%)

USD 97.17B
LLY Eli Lilly and Company

+0.71 (+0.82%)

USD 94.24B
AZN Astrazeneca PLC

-0.16 (-0.44%)

USD 91.05B
BMY Bristol-Myers Squibb Company

-0.01 (-0.02%)

USD 87.68B
AGN Allergan plc

+1.33 (+0.77%)

USD 58.67B

ETFs Containing MRK

IHE iShares U.S. Pharmaceutic.. 8.26 % 0.44 %

+0.42 (+0.27%)

USD 0.38B
PPH VanEck Vectors Pharmaceut.. 5.47 % 0.35 %

+0.20 (+0.33%)

USD 0.29B
HHL:CA Harvest Healthcare Leader.. 5.33 % 1.24 %

N/A

CAD 0.26B
DJD Invesco Dow Jones Industr.. 5.26 % 0.30 %

-0.14 (-0.43%)

USD 0.01B
LIFE.B:CA Evolve Global Healthcare .. 5.21 % 0.00 %

N/A

CAD 0.49M
LIFE:CA Evolve Global Healthcare .. 5.21 % 0.00 %

N/A

CAD 0.93M
PJP Invesco Dynamic Pharmaceu.. 5.01 % 0.56 %

+0.60 (+0.89%)

USD 0.55B
XLV SPDR Select Sector Fund -.. 4.99 % 0.14 %

+0.22 (+0.26%)

USD 15.93B
IYH iShares U.S. Healthcare 4.69 % 0.44 %

+0.40 (+0.22%)

USD 1.89B
XPH SPDR S&P Pharmaceuticals 4.63 % 0.35 %

+0.22 (+0.50%)

USD 0.35B
FTXH First Trust Nasdaq Pharma.. 4.45 % 0.60 %

-0.01 (-0.03%)

USD 3.27M
RXL ProShares Ultra Health Ca.. 4.39 % 0.95 %

+0.32 (+0.35%)

USD 0.10B
FHLC Fidelity MSCI Health Care.. 4.31 % 0.08 %

+0.15 (+0.36%)

USD 1.18B
VHT Vanguard Health Care 4.31 % 0.10 %

+0.54 (+0.33%)

USD 7.45B
ZWH.U:CA BMO US High Dividend Cove.. 3.99 % 0.72 %

-0.05 (-0.23%)

CAD 0.06B
ZWH:CA BMO US High Dividend Cove.. 3.99 % 0.71 %

+0.06 (+0.29%)

CAD 0.68B
EDOW First Trust Dow 30 Equal .. 3.69 % 0.50 %

-0.30 (-1.34%)

USD 9.89M
PILL Direxion Daily Pharmaceut.. 3.69 % 0.00 %

+0.95 (+3.25%)

USD 4.50M
XHD:CA iShares U.S. High Dividen.. 3.62 % 0.33 %

+0.07 (+0.26%)

CAD 0.21B
XHU:CA iShares U.S. High Dividen.. 3.61 % 0.32 %

+0.08 (+0.35%)

CAD 0.03B
HDV iShares Core High Dividen.. 3.60 % 0.10 %

+0.18 (+0.21%)

USD 5.76B
IXJ iShares Global Healthcare 3.42 % 0.48 %

-0.48 (-0.84%)

USD 1.55B
JHMH John Hancock Multifactor .. 3.17 % 0.50 %

+0.15 (+0.47%)

USD 0.04B
USMC Principal U.S. Mega-Cap M.. 3.10 % 0.00 %

-0.09 (-0.34%)

USD 1.70B
QDYN FlexShares Quality Dynami.. 2.94 % 0.37 %

-0.41 (-0.93%)

USD 0.05B
MOAT VanEck Vectors Morningsta.. 2.68 % 0.48 %

+0.14 (+0.32%)

USD 1.42B
XDU:CA iShares Core MSCI US Qual.. 2.61 % 0.16 %

+0.08 (+0.38%)

CAD 0.02B
QDF FlexShares Quality Divide.. 2.49 % 0.37 %

-0.11 (-0.24%)

USD 1.79B
QDEF FlexShares Quality Divide.. 2.38 % 0.37 %

-0.07 (-0.15%)

USD 0.32B
SDOG ALPS Sector Dividend Dogs 2.31 % 0.40 %

-0.05 (-0.11%)

USD 2.26B
FLQD Franklin LibertyQ Global .. 2.29 % 0.45 %

-0.10 (-0.36%)

USD 0.02B
FLGD:CA Franklin LibertyQT Global.. 2.26 % 0.00 %

N/A

CAD 9.90M
UXM.B:CA First Asset Morningstar U.. 2.21 % 0.66 %

+0.10 (+0.60%)

CAD 0.02B
UXM:CA First Asset Morningstar U.. 2.21 % 0.68 %

-0.02 (-0.14%)

CAD 0.05B
HEA.U:CA Horizons Enhanced Income .. 2.15 % 0.83 %

N/A

CAD 0.04B
DGRO iShares Core Dividend Gro.. 2.10 % 0.09 %

-0.14 (-0.40%)

USD 3.73B
RNDV First Trust US Equity Div.. 2.02 % 0.00 %

-0.09 (-0.40%)

USD 4.36M
ZUH:CA BMO Equal Weight US Healt.. 1.96 % 0.39 %

-0.10 (-0.19%)

CAD 0.33B
XDG:CA iShares Core MSCI Global .. 1.90 % 0.22 %

+0.01 (+0.05%)

CAD 0.04B
RYH Invesco S&P 500 Equal Wei.. 1.81 % 0.40 %

+0.20 (+0.11%)

USD 0.63B
FDRR Fidelity Dividend ETF for.. 1.77 % 0.29 %

-0.12 (-0.39%)

USD 0.34B
OVLC Invesco U.S. Large Cap Op.. 1.77 % 0.30 %

N/A

USD 1.54M
PEU:CA Purpose Enhanced US Equit.. 1.73 % 1.31 %

N/A

CAD 3.37M
PEU.B:CA Purpose Enhanced US Equit.. 1.72 % 1.16 %

N/A

CAD 0.78M
DSI iShares MSCI KLD 400 Soci.. 1.40 % 0.50 %

-0.36 (-0.35%)

USD 1.12B
OEW Invesco S&P 100 Equal Wei.. 1.12 % 0.41 %

N/A

USD 3.32M
CVY Invesco Zacks Multi-Asset.. 1.10 % 0.65 %

-0.05 (-0.22%)

USD 0.29B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.46% 70% C- 82% B-
Dividend Return 1.71% 64% D 59% F
Total Return 10.17% 70% C- 83% B
Trailing 12 Months  
Capital Gain -4.16% 48% F 32% F
Dividend Return 3.00% 69% D+ 48% F
Total Return -1.16% 48% F 29% F
Trailing 5 Years  
Capital Gain 28.27% 63% D 63% D
Dividend Return 19.23% 73% C 58% F
Total Return 47.50% 68% D+ 63% D
Average Annual (5 Year Horizon)  
Capital Gain 4.69% 52% F 58% F
Dividend Return 7.93% 48% F 55% F
Total Return 3.25% 67% D+ 59% F
Risk Return Profile  
Volatility (Standard Deviation) 13.93% 86% B 53% F
Risk Adjusted Return 56.96% 76% C 51% F
Market Capitalization 167.96B 87% B+ 99% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.90 14% F 5% F
Price/Book Ratio 4.79 33% F 17% F
Price / Cash Flow Ratio 5.50 10% F 19% F
Price/Free Cash Flow Ratio 31.14 19% F 19% F
Management Effectiveness  
Return on Equity 4.34% 29% F 33% F
Return on Invested Capital 11.00% 48% F 64% D
Return on Assets 1.76% 33% F 41% F
Debt to Equity Ratio 68.75% 50% F 54% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

MRK:NYE-Merck & Company Inc. (new)

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 61.03

Change

+0.04 (+0.07)%

Market Cap

USD 164.19B

Volume

0.01B

Yahoo Analyst Target

USD 69.06 (13.16%)

STA Analyst Target

USD 64.62 (5.89%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-06-19